Adma Biologics IncのRSI
Adma Biologics IncのRSIは何ですか。
Adma Biologics IncのRSIは58.64です。
RSIの定義は何ですか。
相対力指数 (The relative strength index, RSI 14)は、一定期間における損益の規模を比較して、証券の価格変動の速度と変動を測る指標です。
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
NASDAQのセクタHealth CareにおけるRSIの企業と比べるAdma Biologics Inc
Adma Biologics Incは何をしますか。
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Adma Biologics Incと類似のrsi
- Innovent BiologicsのRSIは58.62です。
- Royal Ahold Delhaize NVのRSIは58.63です。
- Brederode SAのRSIは58.63です。
- Brookfield InfrastructureのRSIは58.63です。
- Huami CorpのRSIは58.63です。
- Prospect Capital CorpのRSIは58.63です。
- Adma Biologics IncのRSIは58.64です。
- Yamana GoldのRSIは58.65です。
- PICC Property and CasualtyのRSIは58.65です。
- SymphonyのRSIは58.65です。
- Moury Construct SAのRSIは58.65です。
- Alexander & BaldwinのRSIは58.65です。
- T-Mobile US IncのRSIは58.65です。